Compare Versions

PDF |Add To My Favorites |Track Bill | print page

SB-356 California Cancer Clinical Trials Program.(2021-2022)

Current Version: 02/09/21 - Introduced Compare Versions information image



Senate Bill
No. 356

Introduced by Senator Archuleta

February 09, 2021

An act to amend Section 101991 of the Health and Safety Code, relating to clinical trials.


SB 356, as introduced, Archuleta. California Cancer Clinical Trials Program.
Existing law provides for the establishment of the California Cancer Clinical Trials Program and requests that the University of California establish or designate an institute or office within the university to administer the program, which is governed by a board of at least 5 members appointed by the president of the university. Existing law also authorizes the program administrator to solicit funds from various specified sources for purposes of the program, and requires the program administrator, upon receipt of at least $500,000 in funding, to establish the Cancer Clinical Trials Grant Program to increase patient access to eligible cancer clinical trials in underserved or disadvantaged communities and populations, as specified.
This bill would make technical, nonsubstantive changes to those provisions.
Vote: MAJORITY   Appropriation: NO   Fiscal Committee: NO   Local Program: NO  

The people of the State of California do enact as follows:


 Section 101991 of the Health and Safety Code is amended to read:

 The university is hereby requested to do all of the following:
(a) Establish or designate an institute or office within the university to administer the program.
(b) Establish the board, to consist of at least five members, appointed by the president of the university to represent institutions and individuals performing, participating in, and supporting eligible cancer clinical trials in California. California, according to the following:
(1) The members shall have varying backgrounds to promote the purposes of this part.
(2) The board shall be qualified through the experience, expertise, and diversity of its members in the design, implementation, and support of clinical trials, and through studying and addressing socioeconomic, ethnic or racial, regional, and other barriers to participation and interventions to remove those barriers.
(3) Efforts shall be made to include representatives of a range of public and private research institutions, health care providers, health care foundations, and patient advocacy organizations.
(4) All persons appointed to the board shall have an interest in increasing and diversifying access to eligible cancer clinical trials and the ability and desire to solicit funds for the purpose of increasing and diversifying access to clinical trials as provided in this part.
(5) Members of the board shall serve without compensation. A board member shall be reimbursed for any actual, necessary, and reasonable expenses incurred in connection with his or her the member’s duties as a board member.
(6) (A) The program administrator may adjust administrative costs available for use in the program based on the size of the program and the funds that are received.
(B) Notwithstanding subparagraph (A), the program administrator shall use no more than 20 percent of the funds that are made available for the program for administrative costs.
(C) Notwithstanding subparagraph (B), in the first year of the program, the program administrator may use more than 20 percent of the funds for administrative costs, in order to fund the costs of establishing the program.
(c) Publicize to National Cancer Institute-Designated Cancer Centers, community organizations, hospitals, hospital associations, industry, health care foundations, and government agencies, the opportunity to submit nominations for board membership to the president of the university.
(d) Publicize the availability of grants made available through the program to organizations described in subdivision (a) of Section 101994.5.